Lingaraja Jena
Mahatma Gandhi Institute of Medical Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Lingaraja Jena.
Genomics & Informatics | 2014
Satish Kumar; Lingaraja Jena; Sneha Galande; Sangeeta Daf; Kanchan Mohod; Ashok K. Varma
Human papillomavirus (HPV) infection is the leading cause of cancer mortality among women worldwide. The life-threatening infection caused by HPV demands the need for designing anticancerous drugs. In the recent years, different compounds from natural origins, such as carrageenan, curcumin, epigallocatechin gallate, indole-3-carbinol, jaceosidin, and withaferin, have been used as a hopeful source of anticancer therapy. These compounds have been shown to suppress HPV infection by different researchers. In the present study, we explored these natural inhibitors against E6 oncoprotein of high-risk HPV-16, which is known to inactivate the p53 tumor suppressor protein. A robust homology model of HPV-16 E6 was built to anticipate the interaction mechanism of E6 oncoprotein with natural inhibitory molecules using a structure-based drug designing approach. Docking analysis showed the interaction of these natural compounds with the p53-binding site of E6 protein residues 113-122 (CQKPLCPEEK) and helped the restoration of p53 functioning. Docking analysis, besides helping in silico validation of natural compounds, also helps understand molecular mechanisms of protein-ligand interactions.
The International Journal of Mycobacteriology | 2014
Lingaraja Jena; Pranita Waghmare; Supriya Kashikar; Satish Kumar; B. C. Harinath
Tuberculosis (TB) is an ancient disease caused by Mycobacterium tuberculosis (MTB), which remains a major cause for morbidity and mortality in several developing countries. Most drug-resistant MTB clinical strains are resistant to isoniazid (INH), a first-line anti-TB drug. Mutation in KatG, a catalase-peroxidase, of MTB is reported to be a major cause of INH resistance. Normally upon activation by KatG, INH is converted to an active intermediate which has antimycobacterial action in MTB. This INH intermediate in the presence of NADH forms INH-NAD adduct which inhibits inhA (2-trans-enoyl-acyl carrier protein reductase) of MTB, thus blocking the synthesis of mycolic acid, a major lipid of the mycobacterial cell wall. In this docking study, the high binding affinity of INH-NAD adduct towards InhA was observed in comparison with INH alone. In this study, two resistant mutants of KatG (S315T and S315N) were modeled using Modeller9v10 and docking analysis with INH was performed using AutoDock4.2 and the docking results of these mutants were compared with the wild type KatG. Docking results revealed the formation of a single hydrogen (H) bond between the secondary amine nitrogen (-NH) of INH with Thr or Asn residues in place of Serine at 315 position of KatG mutant strains respectively, whereas in the case of the wild type, there was no H-bond formation observed between INH and Ser315. The H-bond formation may prevent free radical formation by KatG in mutant strains thus the development of resistance to the drug. This in silico evidence may implicate the basis of INH resistance in KatG mutant strains.
Interdisciplinary Sciences: Computational Life Sciences | 2015
Satish Kumar; Lingaraja Jena; Kanchan Mohod; Sangeeta Daf; Ashok K. Varma
Human papillomavirus (HPV), a life-threatening infection, is the leading cause of cancer mortality among women worldwide and needs for designing anticancerous drugs. In the present study, we explored specific novel inhibitors against E6 oncoprotein of high-risk HPV 16, known to inactivate tumor suppressor p53 protein. A homology model of HPV 16 E6 was built and validated using bioinformatics approach. A total of 5000 drug-like compounds were downloaded from ZINC database based on the properties similar to the known inhibitor Jaceosidin (5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-6-methoxy-4H-chromen-4-one). Virtual-ligand-screening approaches were applied to screen appropriate drug-like compounds using molecular docking program AutoDock Vina in PyRx 0.8, and five best novel drug-like compounds were identified as potential competitive inhibitors against HPV 16 E6 compared to Jaceosidin. Two among these five identified most potential inhibitors, N-[(5-methyl-1H-benzimidazol-2-yl)methyl]-4-oxo-3,4-dihydrophthalazine-1-carboxamide and 6-[3-(3-fluoro-4-methyl-phenyl)-1,2,4-oxadiazol-5-yl]-1,4-dihydroquinoxaline-2,3-dione, were found to interact with E6 with binding energy of
Genomics & Informatics | 2014
Satish Kumar; Lingaraja Jena
Genomics & Informatics | 2013
Satish Kumar; Lingaraja Jena; Sangeeta Daf; Kanchan Mohod; Peyush Goyal; Ashok K. Varma
-7.7
The International Journal of Mycobacteriology | 2013
Lingaraja Jena; Supriya Kashikar; Satish Kumar; B. C. Harinath
Mycobacterial Diseases | 2016
Pranita Waghmare; Gauri Wankhade; Lingaraja Jena; B. C. Harinath
-7.7 and
Journal of Infectious Diseases and Therapy | 2016
Lingaraja Jena; Tapaswini Nayak; Shraddha Deshmukh; Gauri Wankhade; Pranita Waghmare; B. C. Harinath
The International Journal of Mycobacteriology | 2015
Lingaraja Jena; Shraddha Deshmukh; Pranita Waghmare; Satish Kumar; B. C. Harinath
-7.0
Interdisciplinary Sciences: Computational Life Sciences | 2017
Dibyabhaba Pradhan; Monika Yadav; Rashi Verma; Noor Saba Khan; Lingaraja Jena; Arun Kumar Jain